We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?
Read MoreHide Full Article
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to release third-quarter fiscal 2020 results on Aug 6, before the opening bell.
BD delivered an earnings surprise of 11.8% in the last reported quarter. It beat estimates in each of the trailing four quarters, the average surprise being 3.5%.
Q3 Estimates
For the quarter to be reported, the Zacks Consensus Estimate for BD’s adjusted earnings per share (EPS) is pegged at $2.04, suggesting a decline of 33.8% from the prior-year quarter. The same for revenues stands at $3.92 billion, indicating a decrease of 9.8% from the year-ago reported quarter.
BD Life Sciences: A Key Catalyst
BD Life Sciences’ fiscal third-quarter performance is likely to reflect strong year-over-year growth in revenues from assays, which are used to detect a broad range of infectious diseases, healthcare-associated infections and cancer.
Notably, strong performance by the Diagnostic Systems and Biosciences sub-units may have contributed to the to-be-reported quarter’s performance.
Growth in licensing revenues and demand for instruments and reagents might have benefited the Bioscience sub-unit’s performance.
Becton, Dickinson and Company Price and EPS Surprise
It is important to mention here that BD has been focusing on fighting the coronavirus pandemic.
In April, the company received Emergency Use Authorization (EUA) from the FDA for an additional molecular diagnostic test for COVID-19 that can present results within a time frame of two to three hours. Notably, the test has also been CE marked to the In Vitro Diagnostics medical devices (IVD) Directive (98/79/EC). The test offers additional testing capacity for COVID-19 in the United States and other countries that consider the CE Mark to test patients and health care workers.
The segment is likely to have received a boost from the introduction of the test, which in turn might get reflected in the fiscal third-quarter results.
Further, during the fiscal second quarter, BD closed the acquisition of NAT Diagnostics, an early-stage company with a very innovative platform in the fast-growing molecular point-of-care market. This buyout will strengthen BD's presence in the molecular point-of-care testing market. This acquisition may have favored the company’s fiscal third-quarter performance.
Other Factors to Note
Strong performance by the BD Interventional arm might get reflected in the company’s fiscal third-quarter results.
The company is likely to have witnessed strong performance in peripheral intervention, which comprises WavelinQ, Covera and Venovo products.
BD expects its Critical Care business and the Arctic Sun Stat launch under its Interventional arm to have driven the segment’s fiscal third-quarter performance.
Robust product pipeline is likely to have contributed to the fiscal third-quarter performance.
However, the company anticipates fiscal third-quarter results to reflect the impact of foreign exchange headwinds.
Also, the company is likely to have witnessed fall in revenues at its BD Medical segment in the to-be-reported quarter primarily due to weakness across Medication Management Solutions and Medication Delivery Solutions units.
What the Zacks Model Unveils
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see below.
Earnings ESP: BD has an Earnings ESP of +1.54%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
GW Pharmaceuticals plc has an Earnings ESP of +17.38% and a Zacks Rank of 3.
Nevro Corp. (NVRO - Free Report) has an Earnings ESP of +15.17% and a Zacks Rank of 3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in Store for Becton, Dickinson's (BDX) Q3 Earnings?
Becton, Dickinson and Company (BDX - Free Report) , popularly known as BD, is scheduled to release third-quarter fiscal 2020 results on Aug 6, before the opening bell.
BD delivered an earnings surprise of 11.8% in the last reported quarter. It beat estimates in each of the trailing four quarters, the average surprise being 3.5%.
Q3 Estimates
For the quarter to be reported, the Zacks Consensus Estimate for BD’s adjusted earnings per share (EPS) is pegged at $2.04, suggesting a decline of 33.8% from the prior-year quarter. The same for revenues stands at $3.92 billion, indicating a decrease of 9.8% from the year-ago reported quarter.
BD Life Sciences: A Key Catalyst
BD Life Sciences’ fiscal third-quarter performance is likely to reflect strong year-over-year growth in revenues from assays, which are used to detect a broad range of infectious diseases, healthcare-associated infections and cancer.
Notably, strong performance by the Diagnostic Systems and Biosciences sub-units may have contributed to the to-be-reported quarter’s performance.
Growth in licensing revenues and demand for instruments and reagents might have benefited the Bioscience sub-unit’s performance.
Becton, Dickinson and Company Price and EPS Surprise
Becton, Dickinson and Company price-eps-surprise | Becton, Dickinson and Company Quote
It is important to mention here that BD has been focusing on fighting the coronavirus pandemic.
In April, the company received Emergency Use Authorization (EUA) from the FDA for an additional molecular diagnostic test for COVID-19 that can present results within a time frame of two to three hours. Notably, the test has also been CE marked to the In Vitro Diagnostics medical devices (IVD) Directive (98/79/EC). The test offers additional testing capacity for COVID-19 in the United States and other countries that consider the CE Mark to test patients and health care workers.
The segment is likely to have received a boost from the introduction of the test, which in turn might get reflected in the fiscal third-quarter results.
Further, during the fiscal second quarter, BD closed the acquisition of NAT Diagnostics, an early-stage company with a very innovative platform in the fast-growing molecular point-of-care market. This buyout will strengthen BD's presence in the molecular point-of-care testing market. This acquisition may have favored the company’s fiscal third-quarter performance.
Other Factors to Note
Strong performance by the BD Interventional arm might get reflected in the company’s fiscal third-quarter results.
The company is likely to have witnessed strong performance in peripheral intervention, which comprises WavelinQ, Covera and Venovo products.
BD expects its Critical Care business and the Arctic Sun Stat launch under its Interventional arm to have driven the segment’s fiscal third-quarter performance.
Robust product pipeline is likely to have contributed to the fiscal third-quarter performance.
However, the company anticipates fiscal third-quarter results to reflect the impact of foreign exchange headwinds.
Also, the company is likely to have witnessed fall in revenues at its BD Medical segment in the to-be-reported quarter primarily due to weakness across Medication Management Solutions and Medication Delivery Solutions units.
What the Zacks Model Unveils
Per our proven model, a combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is the case here as you will see below.
Earnings ESP: BD has an Earnings ESP of +1.54%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Other Stocks Worth a Look
Here are some other medical stocks worth considering as these too have the right combination of elements to post an earnings beat this quarter.
Integra LifeSciences Holdings Corporation (IART - Free Report) has an Earnings ESP of +20.69% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.
GW Pharmaceuticals plc has an Earnings ESP of +17.38% and a Zacks Rank of 3.
Nevro Corp. (NVRO - Free Report) has an Earnings ESP of +15.17% and a Zacks Rank of 3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>